Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG in Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
NCT02019056Phase 2Completed
- Sponsor
- PharmaKing
- Start
- Nov 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metadoxine + garlic oil in Alcoholic Fatty Liver Disease (AFLD) and alcoholic hepatitis (AH) (4 arms), sponsored by PharmaKing. Primary endpoints: Change from Baseline in AST at 14 weeks, Number of Participants with Adverse Events at 14 weeks and 3 more. Started Nov 2010; status: completed.
02
Drugs
metadoxine + garlic oil
03
Conditions
Alcoholic Fatty Liver Disease (AFLD)alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT02019056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019056.